CSIMarket
 


Moderna Inc   (MRNA)
Other Ticker:  
 
 

MRNA's Capital Expenditures Growth by Quarter and Year

Moderna Inc 's Capital Expenditures results by quarter and year




MRNA Capital Expenditures (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December 92.00 120.00 23.30 0.00
III Quarter September 89.00 99.00 19.29 0.00
II Quarter June 87.00 30.00 18.63 0.00
I Quarter March 132.00 35.00 6.22 0.00
FY   400.00 284.00 67.44 0.00



MRNA Capital Expenditures fourth quarter 2022 Y/Y Growth Comment
Moderna Inc reported decline in Capital Expenditures in the fourth quarter 2022 by -23.33% to $ 92.00 millions, from the same quarter in 2021.
The contraction in the fourth quarter 2022 Moderna Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures doubling of 136.23%.

Looking into fourth quarter 2022 results within Biotechnology & Pharmaceuticals industry 5 other companies have achieved higher Capital Expenditures growth. While Moderna Inc ' s Capital Expenditures fall of -23.33% ranks overall at the positon no. 333 in the fourth quarter 2022.




MRNA Capital Expenditures ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December -23.33 % 415.02 % - -
III Quarter September -10.1 % 413.22 % - -
II Quarter June 190 % 61.03 % - -
I Quarter March 277.14 % 462.7 % - -
FY   40.85 % 321.12 % - -

Financial Statements
Moderna Inc 's fourth quarter 2022 Capital Expenditures $ 92.00 millions MRNA's Income Statement
Moderna Inc 's fourth quarter 2021 Capital Expenditures $ 120.00 millions Quarterly MRNA's Income Statement
New: More MRNA's historic Capital Expenditures Growth >>


MRNA Capital Expenditures (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December 3.37 % 21.21 % 20.79 % -
III Quarter September 2.3 % 230 % 3.54 % -
II Quarter June -34.09 % -14.29 % 199.52 % -
I Quarter March 10 % 50.21 % - -
FY (Year on Year)   40.85 % 321.12 % - -




Capital Expenditures fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #6
Healthcare Sector #46
Overall #333

Capital Expenditures Y/Y Growth Statistics
High Average Low
321.07 % 136.23 % 0 %
(Dec 31 2021)   (Mar 31 2023)
Capital Expenditures fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #6
Healthcare Sector #46
Overall #333
Capital Expenditures Y/Y Growth Statistics
High Average Low
321.07 % 136.23 % 0 %
(Dec 31 2021)   (Mar 31 2023)

Capital Expenditures by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Moderna Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
230 % 23.22 % -100 %
(Sep 30 2021)  


MRNA's IV. Quarter Q/Q Capital Expenditures Comment
Moderna Inc achieved in the IV. Quarter 2022 below company average Capital Expenditures growth of 3.37% quarter on quarter, to $ 92.00 millions.

Within Biotechnology & Pharmaceuticals industry 13 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Moderna Inc 's Capital Expenditures growth quarter on quarter, overall rank is 764.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #14
Healthcare Sector #119
Overall #764
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #14
Healthcare Sector #119
Overall #764
Capital Expenditures Q/Q Growth Statistics
High Average Low
230 % 23.22 % -100 %
(Sep 30 2021)  


MRNA's IV. Quarter Q/Q Capital Expenditures Comment
Moderna Inc achieved in the IV. Quarter 2022 below company average Capital Expenditures growth of 3.37% quarter on quarter, to $ 92.00 millions.

Within Biotechnology & Pharmaceuticals industry 13 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Moderna Inc 's Capital Expenditures growth quarter on quarter, overall rank is 764.


Moderna Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
Cumulative Capital Expenditures 12 Months Ending $ 400.00 $ 428.00 $ 438.00 $ 381.00 $ 284.00
Y / Y Capital Expenditures Growth (TTM) 40.85 % 128.51 % 307.09 % 295.95 % 321.07 %
Year on Year Capital Expenditures Growth Overall Ranking # 25 # 0 # 0 # 0 # 238
Seqeuential Capital Expenditures Change (TTM) -6.54 % -2.28 % 14.96 % 34.15 % 51.63 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 333 # 446 # 834 # 686 # 363




Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Dec 31 2022 period, Moderna Inc 's cumulative twelve months Capital Expenditures were $ 400 millions, company would post below average annual Capital Expenditures growth of 51.63% year on year, if the fiscal year would end at Dec 31 2022.
A slow-down in the Moderna Inc 's Capital Expenditures growth from the 89% growth in Sep 30 2022.

Among companies within the Healthcare sector 3 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 0 to 25.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
321.07 %
136.23 %
0 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 6
Healthcare Sector # 4
Overall # 25

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
321.07 %
136.23 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 46
S&P 500 # 333
Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Dec 31 2022 period, Moderna Inc 's cumulative twelve months Capital Expenditures were $ 400 millions, company would post below average annual Capital Expenditures growth of 0% year on year, if the fiscal year would end at Dec 31 2022.
A slow-down in the Moderna Inc 's Capital Expenditures growth from the 89% growth in Sep 30 2022.

Among companies within the Healthcare sector 3 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 0 to 25.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
321.07 %
136.23 %
0 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 6
Healthcare Sector # 4
Overall # 25

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
321.07 %
136.23 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 46
S&P 500 # 333




Other Capital Expenditures Growth
Biotechnology & Pharmaceuticals Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
MRNA's Capital Expenditures Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for MRNA's Competitors
Capital Expenditures Growth for Moderna Inc 's Suppliers
Capital Expenditures Growth for MRNA's Customers

You may also want to know
MRNA's Annual Growth Rates MRNA's Profitability Ratios MRNA's Asset Turnover Ratio MRNA's Dividend Growth
MRNA's Roe MRNA's Valuation Ratios MRNA's Financial Strength Ratios MRNA's Dividend Payout Ratio
MRNA's Roa MRNA's Inventory Turnover Ratio MRNA's Growth Rates MRNA's Dividend Comparisons



Companies with similar Capital Expenditures growth for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2022
Encompass Health Corporation-0.10%$ -0.099 millions
Abbott Laboratories-0.65%$ -0.651 millions
Qualigen Therapeutics Inc -0.69%$ -0.687 millions
Rxsight Inc -0.82%$ -0.822 millions
Cryoport inc -0.94%$ -0.936 millions
Acadia Healthcare Company Inc -0.94%$ -0.941 millions
Alnylam Pharmaceuticals Inc -1.15%$ -1.147 millions
Achilles Therapeutics Plc-1.60%$ -1.598 millions
Regeneron Pharmaceuticals Inc -1.74%$ -1.743 millions
Warby Parker Inc -1.93%$ -1.932 millions
Gsk Plc-2.47%$ -2.474 millions
Emergent Biosolutions Inc -2.78%$ -2.784 millions
Ligand Pharmaceuticals Incorporated-2.92%$ -2.916 millions
Community Health Systems Inc -2.96%$ -2.963 millions
Vir Biotechnology Inc -3.60%$ -3.604 millions
1life Healthcare Inc -4.08%$ -4.082 millions
Henry Schein Inc-4.32%$ -4.319 millions
Pharvaris N v -4.41%$ -4.411 millions
Tenet Healthcare Corp-4.61%$ -4.605 millions
Merck and Co Inc -4.88%$ -4.884 millions
Edwards Lifesciences Corporation-5.01%$ -5.011 millions
Veru Inc -5.51%$ -5.507 millions
Opko Health Inc -5.85%$ -5.854 millions
Cano Health Inc -5.97%$ -5.973 millions
Axogen inc -6.31%$ -6.311 millions
Si bone inc -6.48%$ -6.479 millions
Qilian International Holding Group Limited-6.71%$ -6.710 millions
Treace Medical Concepts Inc -7.05%$ -7.055 millions
Iqvia Holdings Inc -7.07%$ -7.065 millions
Teva Pharmaceutical Industries Limited-7.19%$ -7.190 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com